The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial

Table 3 Within- and between-group comparisons of the clinical outcomes from baseline to the end of the intervention

Variables	Positive cases	Clinical outcomes		P value^†	P value*
Variables	Positive cases	Improving	No change	P value^†	P value*
Dry cough	Curcumin group: 13	10	3	0.002	1
Dry cough	Placebo group: 13	10	3	0.002	1
Sputum cough	Curcumin group: 8	7	1	0.008	0.788
Sputum cough	Placebo group: 7	6	1	0.014	0.788
Ague	Curcumin group: 6	4	2	0.046	0.366
Ague	Placebo group: 7	7	0	0.008	0.366
Sore throat	Curcumin group: 7	5	2	0.025	0.626
Sore throat	Placebo group: 6	5	1	0.025	0.626
Weakness	Curcumin group: 12	10	2	0.002	0.025
Weakness	Placebo group: 13	5	8	0.025	0.025
Muscular pain	Curcumin group: 10	7	3	0.008	0.337
Muscular pain	Placebo group: 14	7	7	0.008	0.337
Headache	Curcumin group: 13	9	4	0.003	0.390
Headache	Placebo group: 8	4	4	0.046	0.390
Dyspnea	Curcumin group: 8	5	3	0.025	0.441
Dyspnea	Placebo group: 6	5	1	0.025	0.441

ISSN: 1745-6215